H.C. Wainwright analyst Emily Bodnar maintained a Buy rating on Nkarta today and set a price target of $18.00.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Emily Bodnar’s rating is based on the promising developments in Nkarta’s clinical trials and the potential of their NKX019 therapy. The company is preparing to release preliminary data from their Ntrust-1 and Ntrust-2 clinical trials in the second half of 2025, which will provide the first insights into the efficacy of NKX019 for treating various autoimmune diseases. These trials are significant as they enroll patients with conditions such as lupus nephritis, systemic sclerosis, and idiopathic inflammatory myopathy, using a regimen that could offer a competitive edge in the field of CAR-NK therapies.
Additionally, Nkarta is conducting investigator-sponsored trials for NKX019 in other autoimmune diseases like systemic lupus erythematosus and myasthenia gravis, with data expected in 2026. The potential success of these trials could position Nkarta favorably against competitors, as the data will allow for direct comparisons and could demonstrate high response rates and drug-free remission. These factors contribute to the positive outlook and justify the Buy rating given by Emily Bodnar.
According to TipRanks, Bodnar is an analyst with an average return of -6.1% and a 27.06% success rate. Bodnar covers the Healthcare sector, focusing on stocks such as Olema Pharmaceuticals, Agios Pharma, and Agenus.
In another report released today, Needham also maintained a Buy rating on the stock with a $10.00 price target.